[go: up one dir, main page]

DK1313485T3 - Anvendelse af en aldosteronreceptorantagonist til forbedring af kognitiv funktion - Google Patents

Anvendelse af en aldosteronreceptorantagonist til forbedring af kognitiv funktion

Info

Publication number
DK1313485T3
DK1313485T3 DK01964471T DK01964471T DK1313485T3 DK 1313485 T3 DK1313485 T3 DK 1313485T3 DK 01964471 T DK01964471 T DK 01964471T DK 01964471 T DK01964471 T DK 01964471T DK 1313485 T3 DK1313485 T3 DK 1313485T3
Authority
DK
Denmark
Prior art keywords
receptor antagonist
aldosterone receptor
cognitive function
improve cognitive
aldosterone
Prior art date
Application number
DK01964471T
Other languages
English (en)
Inventor
Kenton N Fedde
Alfonzo T Perez
Joseph F Tooley
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Application granted granted Critical
Publication of DK1313485T3 publication Critical patent/DK1313485T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK01964471T 2000-08-28 2001-08-28 Anvendelse af en aldosteronreceptorantagonist til forbedring af kognitiv funktion DK1313485T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22873800P 2000-08-28 2000-08-28

Publications (1)

Publication Number Publication Date
DK1313485T3 true DK1313485T3 (da) 2005-12-27

Family

ID=22858397

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01964471T DK1313485T3 (da) 2000-08-28 2001-08-28 Anvendelse af en aldosteronreceptorantagonist til forbedring af kognitiv funktion

Country Status (10)

Country Link
US (2) US20020111337A1 (da)
EP (1) EP1313485B1 (da)
JP (1) JP2004507495A (da)
AT (1) ATE306272T1 (da)
AU (1) AU2001285318A1 (da)
CA (1) CA2419256A1 (da)
DE (1) DE60114027T2 (da)
DK (1) DK1313485T3 (da)
ES (1) ES2251505T3 (da)
WO (1) WO2002017895A2 (da)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005513024A (ja) * 2001-11-23 2005-05-12 アクゾ・ノベル・エヌ・ベー グルココルチコイド受容体アンタゴニストを用いる大うつ病性障害の治療
NZ548754A (en) * 2002-04-26 2008-06-30 Schering Aktiengellschaft Treatment of hypertension in women receiving hormone replacement therapy
TW200400816A (en) 2002-06-26 2004-01-16 Lilly Co Eli Tricyclic steroid hormone nuclear receptor modulators
WO2004041288A1 (en) * 2002-11-05 2004-05-21 Schering Aktiengesellschaft Hormone replacement therapy with drospirenone
US7786101B2 (en) * 2002-11-05 2010-08-31 Bayer Schering Pharma Ag Cardiovascular protection using anti-aldosteronic progestins
JP2006508945A (ja) * 2002-11-05 2006-03-16 シエーリング アクチエンゲゼルシャフト 抗−アルドステロン性プロゲスチンを用いての心血管保護
JPWO2004060400A1 (ja) * 2003-01-06 2006-05-11 那波　宏之 上皮成長因子受容体を分子標的とする抗精神病薬
US7485094B2 (en) * 2003-09-30 2009-02-03 Smithmarks, Inc. Methods of diagnosis using pulse volume measurement
EP2051696A2 (en) * 2006-08-18 2009-04-29 Morton Grove Pharmaceuticals, Inc. Stable liquid levetiracetam compositions and methods
US20090265215A1 (en) * 2008-04-22 2009-10-22 Paul Bernhard Lindstrom Methods and apparatus to monitor audience exposure to media using duration-based data
WO2012059594A1 (en) * 2010-11-04 2012-05-10 Bayer Pharma Aktiengesellschaft Mineralcorticoid receptor antagonists for the treatment of corticoid-induced obesity
ES2618812T3 (es) 2011-01-20 2017-06-22 Merck Sharp & Dohme Corp. Antagonistas del receptor mineralocorticoide
WO2012139495A1 (en) 2011-04-13 2012-10-18 Merck Sharp & Dohme Corp. Mineralocorticoid receptor antagonists
WO2013055608A1 (en) 2011-10-13 2013-04-18 Merck Sharp & Dohme Corp. Mineralocorticoid receptor antagonists
US9193717B2 (en) 2011-10-13 2015-11-24 Merck Sharp & Dohme Corp. Mineralocorticoid receptor antagonists
EP2765859B1 (en) 2011-10-13 2017-01-18 Merck Sharp & Dohme Corp. Mineralocorticoid receptor antagonists
AR091731A1 (es) 2012-07-19 2015-02-25 Merck Sharp & Dohme Antagonistas del receptor de mineralocorticoides
WO2017083795A1 (en) * 2015-11-13 2017-05-18 Pietro Paolo Sanna Methods and compositions for treating alcohol use disorders

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3133012A (en) * 1961-06-28 1964-05-12 Universal Oil Prod Co Combination catalytic reforming process
US3257390A (en) * 1963-06-12 1966-06-21 Merck & Co Inc Ring a unsaturated 21-hydroxy-3-oxo-17alpha-pregnane-17-carboxylic acid lactone diuretic agents
IE51145B1 (en) * 1980-03-07 1986-10-15 Efamol Ltd Pharmaceutical and dietary compositions
US4559332A (en) * 1983-04-13 1985-12-17 Ciba Geigy Corporation 20-Spiroxanes and analogues having an open ring E, processes for their manufacture, and pharmaceutical preparations thereof
DE3506100A1 (de) * 1985-02-18 1986-08-21 Schering AG, 1000 Berlin und 4709 Bergkamen 1(alpha).7(alpha)-dithiosubstituierte spirolactone, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
FR2634376B1 (fr) * 1988-07-21 1992-04-17 Farmalyoc Nouvelle forme unitaire, solide et poreuse comprenant des microparticules et/ou des nanoparticules, ainsi que sa preparation
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
AU642066B2 (en) * 1991-01-25 1993-10-07 Nanosystems L.L.C. X-ray contrast compositions useful in medical imaging
US5529992A (en) * 1992-04-21 1996-06-25 Curators Of The University Of Missouri Method for inhibiting myocardial fibrosis by administering an aldosterone antagonist which suppresses aldoster one receptors
US5747001A (en) * 1995-02-24 1998-05-05 Nanosystems, L.L.C. Aerosols containing beclomethazone nanoparticle dispersions
CN100369927C (zh) * 1996-12-11 2008-02-20 G·D·瑟尔公司 9,11-环氧甾族化合物和其中有用的中间体的制备方法
DE19654609A1 (de) * 1996-12-20 1998-06-25 Schering Ag Therapeutische Gestagene zur Behandlung von Premenstrual Dysphoric Disorder
WO2000027380A2 (en) * 1998-11-06 2000-05-18 G.D. Searle & Co. Combination therapy of angiotensin converting enzyme inhibitor and aldosterone antagonist for reducing morbidity and mortality from cardiovascular disease
UA74141C2 (uk) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
EP1382351B8 (en) * 1999-03-05 2006-03-08 G.D. Searle LLC. Combination therapy of angiotensin converting enzyme inhibitor and epoxy-steroidal aldosterone antagonist for treatment of cardiovascular disease

Also Published As

Publication number Publication date
CA2419256A1 (en) 2002-03-07
DE60114027T2 (de) 2006-07-13
DE60114027D1 (de) 2006-02-23
US20060058274A1 (en) 2006-03-16
US20020111337A1 (en) 2002-08-15
EP1313485B1 (en) 2005-10-12
AU2001285318A1 (en) 2002-03-13
ATE306272T1 (de) 2005-10-15
ES2251505T3 (es) 2006-05-01
JP2004507495A (ja) 2004-03-11
WO2002017895A3 (en) 2003-02-06
WO2002017895A2 (en) 2002-03-07
EP1313485A2 (en) 2003-05-28

Similar Documents

Publication Publication Date Title
DK1313485T3 (da) Anvendelse af en aldosteronreceptorantagonist til forbedring af kognitiv funktion
PT1349839E (pt) Derivados de feniletenilo ou feniletinilo como antagonistas do receptor de glutamato
MXPA03004832A (es) Compuestos y sus usos.
DK1339678T3 (da) Selektive agonister til EP4-receptor til behandling af osteoporose
NZ548954A (en) Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
YU45293A (sh) Morfolin i tiomorfolin tahikinin antagonisti receptora
MA28110A1 (fr) Antagonistes du recepteur d'acetylcholine muscarinique
SG163564A1 (en) Kinin antagonists for treating bladder dysfunction
MA27900A1 (fr) Antagonistes du recepteur de l'acetylcholine muscarinique
MA27901A1 (fr) Antagonistes du recepteur de l'acetylcholine muscarinique
HN2003000285A (es) Nuevas quinazolinonas espirocondensadas y su uso como inhibidores de la fosfodiesterasa
ATE311200T1 (de) Verfahren und zusammensetzungen zur behandlung von allergischen zuständen mit pgd2 rezeptor antagonisten
DK1117403T3 (da) MGLUR5-antagonister til behandling af smerte og angst
TW200503730A (en) Combination of an aldosterone receptor antagonist and an endothelin receptor antagonist and/or endothelin converting enzyme inhibitor
ECSP066486A (es) Antagonistas de receptores de acetilcolina muscarínicos ii
NO20034311D0 (no) CCR5-antagonister for behandling av AIDS
DE60203797D1 (de) Benzo[d]azepin-derivative als 5-ht6-rezeptor-antagonisten
ATE407122T1 (de) Azadecalinmodulatoren des glucocorticoidrezeptors
NO20016246L (no) Selektiv iGluR5 reseptorantagonist for behandling av migrene
UY28646A1 (es) Nuevos antagonistas del receptor muscarinico m3 de acetilcolina
UY28645A1 (es) Nuevos antagonistas del receptor muscarinico m3 de acetilcolina
MXPA05007605A (es) Antagonista del receptor de androgenos.
AU1604001A (en) Use of an aldosterone antagonist for the treatment or prohpylaxis of aldosterone-mediated pathogenic effects
DE60126134D1 (de) Crf-rezeptorantagonisten und diese betreffende verfahren
DK1146872T3 (da) Anvendelse af angiotensin II-receptorantagonister til behandling af akut myokardieinfarkt